Quantitative assessment of promoter methylation profiles in thyroid neoplasms.

CONTEXT Cancer-specific molecular markers are needed to supplement the cytopathological assessment of thyroid tumors, because a majority of patients with cytologically indeterminate nodules currently undergo thyroidectomy without a definitive diagnosis. OBJECTIVE The aim of this study was the quantitative assessment of promoter hypermethylation and its relation to the BRAF mutation in thyroid tumors. DESIGN Quantitative hypermethylation of Rassf1A, TSHR, RAR-beta2, DAPK, S100, p16, CDH1, CALCA, TIMP3, TGF-beta, and GSTpi was tested on a cohort of 82 benign and malignant thyroid tumors and five thyroid cancer cell lines. SETTING The study was conducted at a tertiary research hospital. PATIENTS Patients underwent surgical resection for a thyroid tumor from 2000 to 2003 at our institution. INTERVENTIONS There were no interventions. MAIN OUTCOME MEASURE Final surgical pathology diagnosis was the main outcome measure. RESULTS Thyroid tumors showed hypermethylation for the following markers: Rassf1A, TSHR, RAR-beta2, DAPK, CDH1, TIMP3, and TGF-beta. A trend toward multiple hypermethylation was evident in cancer tissues, with hypermethylation of two or more markers detectable in 25% of hyperplasias, 38% of adenomas, 48% of thyroid cancers, and 100% of cell lines. A rank correlation analysis of marker hypermethylation suggests that a subset of these markers is epigenetically modified in concert, which may reflect an organ-specific regulation process. Furthermore, a positive correlation was found between the BRAF mutation and RAR-beta2, and a negative correlation was found between the BRAF mutation and Rassf1A. CONCLUSIONS Methylation-induced gene silencing appears to affect multiple genes in thyroid tissue and increases with cancer progression. Additional markers with better discriminatory power between benign and malignant samples are needed for the diagnostic assessment of cytologically indeterminate thyroid nodules.

[1]  P. Ladenson,et al.  BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.

[2]  J. Herman,et al.  Abnormalities of E‐ and P‐cadherin and catenin (β‐, γ‐catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia , 2003 .

[3]  Hwoong-Yong Jung,et al.  Profile of Aberrant CpG Island Methylation along Multistep Gastric Carcinogenesis , 2003, Laboratory Investigation.

[4]  J. Fagin,et al.  Genetic and epigenetic alterations of the cyclin‐dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas , 1998, Cancer.

[5]  A. Jauch,et al.  Genetics of neuroendocrine and carcinoid tumours. , 2003, Endocrine-related cancer.

[6]  C. Wild,et al.  Tissue inhibitor of metalloproteinase‐3 (TIMP‐3) gene is methylated in the development of esophageal adenocarcinoma: Loss of expression correlates with poor prognosis , 2005, International journal of cancer.

[7]  D. Clark,et al.  Mutational Analysis of BRAF in Fine Needle Aspiration Biopsies of the Thyroid: A Potential Application for the Preoperative Assessment of Thyroid Nodules , 2004, Clinical Cancer Research.

[8]  S. Wiseman,et al.  TIMP1 and SERPIN‐A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma , 2004, Head & neck.

[9]  J. Califano,et al.  Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer , 2004, Cancer Research.

[10]  P. Ladenson,et al.  Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. , 2003, Cancer research.

[11]  J. Cameron,et al.  Prognostic value of hMLH1 methylation and microsatellite instability in pancreatic endocrine neoplasms. , 2003, Surgery.

[12]  C. R. Leemans,et al.  A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. , 2003, Cancer research.

[13]  E. Medrano,et al.  The emerging role of epigenetics in cellular and organismal aging , 2003, Experimental Gerontology.

[14]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[15]  Jung Weon Lee,et al.  TGF-beta1 (transforming growth factor-beta1)-mediated adhesion of gastric carcinoma cells involves a decrease in Ras/ERKs (extracellular-signal-regulated kinases) cascade activity dependent on c-Src activity. , 2004, The Biochemical journal.

[16]  Y. Tomita,et al.  Role of Hypermethylation of DAP-Kinase CpG Island in the Development of Thyroid Lymphoma , 2000, Laboratory Investigation.

[17]  L. Ward,et al.  GST profiling may be useful in the screening for thyroid nodule malignancy. , 2004, Cancer letters.

[18]  Esteban Ballestar,et al.  Methyl‐CpG binding proteins identify novel sites of epigenetic inactivation in human cancer , 2003, The EMBO journal.

[19]  S. Weitzman,et al.  Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. , 2001, Cancer research.

[20]  S. Pileri,et al.  Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. , 2004, Haematologica.

[21]  C. Moon,et al.  Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer , 2004, Clinical Cancer Research.

[22]  J. Issa,et al.  CpG island methylation in carcinoid and pancreatic endocrine tumors , 2003, Oncogene.

[23]  R. Schneider-Stock,et al.  Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis. , 2003, Pathology, research and practice.

[24]  J. Herman,et al.  Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  M. Fackler,et al.  DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma , 2003, International journal of cancer.

[26]  T. Motoyama,et al.  E‐cadherin expression in follicular carcinoma of the thyroid , 2002, Pathology international.

[27]  A. Miyauchi,et al.  S100A4 Expression Is an Early Event of Papillary Carcinoma of the Thyroid , 2005, Oncology.

[28]  M. Hoque,et al.  Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  J. Herman,et al.  Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. , 1998, Cancer research.

[30]  J. Herman,et al.  Promoter Hypermethylation of Resected Bronchial Margins , 2004, Clinical Cancer Research.

[31]  Yoram Cohen,et al.  Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis , 2004, Cancer Research.

[32]  J. Issa,et al.  Methylation and Regulation of Expression of Different Retinoic Acid Receptor Beta Isoforms in Human Colon Cancer , 2004, Cancer biology & therapy.

[33]  H. Gharib,et al.  Fine-Needle Aspiration Biopsy of the Thyroid: An Appraisal , 1993, Annals of Internal Medicine.

[34]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[35]  S. Baylin,et al.  DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. , 1986, Cancer research.

[36]  M. Brattain,et al.  Restoration of Transforming Growth Factor-β Signaling through Receptor RI Induction by Histone Deacetylase Activity Inhibition in Breast Cancer Cells* , 2004, Journal of Biological Chemistry.

[37]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. , 2003, The American journal of pathology.

[39]  G. Pfeifer,et al.  Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. , 2002, Cancer research.

[40]  D. Sidransky,et al.  BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment , 2004, Modern Pathology.

[41]  S. Weitzman,et al.  Hypermethylation of a Small CpGuanine-Rich Region Correlates with Loss of Activator Protein-2α Expression during Progression of Breast Cancer , 2004, Cancer Research.

[42]  J. Herman,et al.  Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. , 2000, Cancer research.

[43]  A. de la Chapelle,et al.  Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma , 2003, International journal of cancer.

[44]  J. Califano,et al.  The molecular biology of mucosal field cancerization of the head and neck. , 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[45]  T. Yokose,et al.  S‐100 protein is a differentiation marker in thyroid carcinoma of follicular cell origin: An immunohistochemical study , 1997, Pathology international.

[46]  B. Simon,et al.  Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[47]  Tsung-Teh Wu,et al.  Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  P. Gattuso,et al.  Genomic DNA Extraction and PCR Amplification of Exon 15 of the BRAF Gene and Exons 1 and 2 of the NRAS Gene , 2003 .

[49]  Christopher B Umbricht,et al.  Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR , 2001, The Lancet.

[50]  P. Carroll,et al.  Age-dependent methylation of ESR1 gene in prostate cancer. , 2004, Biochemical and biophysical research communications.

[51]  S. Sukumar,et al.  Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer , 2001, Oncogene.

[52]  Y. Shim,et al.  Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. , 2003, Cancer research.

[53]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[54]  Y. Shim,et al.  Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  X. Matías-Guiu,et al.  Abnormalities of the E‐cadherin/catenin adhesion complex in classical papillary thyroid carcinoma and in its diffuse sclerosing variant , 2001, The Journal of pathology.

[56]  B. Boehm,et al.  Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma , 2003, Oncogene.

[57]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.

[58]  V. Fendrich,et al.  Alterations of the Tissue Inhibitor of Metalloproteinase-3 (TIMP3) Gene in Pancreatic Adenocarcinomas , 2005, Pancreas.

[59]  P. Ladenson,et al.  BRAF T1796A transversion mutation in various thyroid neoplasms. , 2004, The Journal of clinical endocrinology and metabolism.

[60]  T. Carling,et al.  Intragenic allelic loss and promoter hypermethylation of the RIZ1 tumor suppressor gene in parathyroid tumors and pheochromocytomas. , 2003, Surgery.

[61]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[62]  M. Nilsson,et al.  N‐cadherin‐mediated adhesion and aberrant catenin expression in anaplastic thyroid‐carcinoma cell lines , 1999, International journal of cancer.